Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsInterest & Investment IncomeNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) EBIT (2020 - 2025)

Historic EBIT for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to -$339.2 million.

  • Roivant Sciences' EBIT fell 2360.66% to -$339.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.2 billion, marking a year-over-year decrease of 12732.26%. This contributed to the annual value of -$1.0 billion for FY2025, which is 12231.01% down from last year.
  • As of Q4 2025, Roivant Sciences' EBIT stood at -$339.2 million, which was down 2360.66% from -$306.2 million recorded in Q3 2025.
  • Roivant Sciences' 5-year EBIT high stood at $5.1 billion for Q4 2023, and its period low was -$684.4 million during Q3 2021.
  • Its 5-year average for EBIT is $64.2 million, with a median of -$280.8 million in 2022.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 33722.03% in 2021, then soared by 145619.33% in 2023.
  • Over the past 5 years, Roivant Sciences' EBIT (Quarter) stood at -$246.0 million in 2021, then crashed by 53.68% to -$378.1 million in 2022, then surged by 1456.19% to $5.1 billion in 2023, then tumbled by 105.35% to -$274.4 million in 2024, then decreased by 23.61% to -$339.2 million in 2025.
  • Its last three reported values are -$339.2 million in Q4 2025, -$306.2 million for Q3 2025, and -$284.9 million during Q2 2025.